Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma

Overview of attention for article published in PLOS ONE, March 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

blogs: 1 blog

policy: 2 policy sources

Citations

dimensions_citation: 55 Dimensions

Readers on

mendeley: 64 Mendeley

Summary Blogs Policy documents Dimensions citations

So far, Altmetric has seen 4 policy documents that reference this research output.

olaparib

Cited by Canadian Agency for Drugs and Technologies in Health on 09 May 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

osimertinib

Cited by Canadian Agency for Drugs and Technologies in Health on 04 Mar 2022

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer : Committee papers

Cited by National Institute for Health and Care Excellence on 02 Mar 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy : Committee papers

Cited by National Institute for Health and Care Excellence on 17 Jul 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.